Dithi Banerjee

Dithi Banerjee

Auto-generated profile, based on publicly available information

Dithi Banerjee

Children's Mercy Kansas City

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 September 2021 in Clinical Infectious Diseases
Verified
Journal Article
Open access
PDF file
EFElizabeth Ross Fraley
Elizabeth Ross Fraley
CLCas LeMaster
Cas LeMaster
SKSantosh Khanal
Santosh Khanal
DBDithi Banerjee
Dithi Banerjee
TPTomi Pastinen
Tomi Pastinen
TBTodd Bradley
Todd Bradley
Determining the duration of immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines is critical for informing the timing of booster immunization. Many genetic and environmental factors could influence both the magnitude and persistence of the antibody response. Here, we showed that SARS-CoV-2 infection before vaccination and age affected the decay of antibody responses to the SARS-CoV-2 messenger RNA vaccine.

19 May 2021 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
PDF file
ASAnjana Sasidharan
Anjana Sasidharan
DBDithi Banerjee
Dithi Banerjee
CHChristopher J Harrison
Christopher J Harrison
RSRangaraj Selvarangan
Rangaraj Selvarangan
Picornaviruses, including Enterovirus species A to D (EV) and Parechovirus species A (PeV-A), are the leading reported causes of pediatric central nervous system infections in the United States. We investigated the molecular epidemiology of EV and PeV-A over 10 years in cerebrospinal fluid (CSF) collected from children seen at Children’s Mercy-Kansas City (CMKC) from 2007 through 2016.

1 January 2025 in Indoor Air
Verified
Journal Article
Open access
OAOlivia Almendares
Olivia Almendares
JRJasmine D. Ruffin
Jasmine D. Ruffin
LGLuke C. Gard
Luke C. Gard
RSRangaraj Selvarangan
Rangaraj Selvarangan
ASAnjana Sasidharan
Anjana Sasidharan
HKHannah L. Kirking
Hannah L. Kirking
Background/Objectives: Respiratory viruses circulate year‐round and can spread indoors via inhalation of airborne particles. Effective ventilation and filtration may reduce transmission, particularly in school settings where children and staff spend significant time. This study examines the impact of indoor air quality (IAQ) and ventilation in schools on respiratory virus detection. Methods: During February 27 to March 30, 2023, we assessed the relationship between IAQ and respiratory viruses in two Kansas City, Missouri, elementary schools by collecting bioaerosol samples, student and staff nasal swabs, and monitoring IAQ across 10 rooms (six classrooms, two common spaces, and two nurses’ offices). We calculated air changes per hour (ACH) and analyzed viral detections in nasal swabs and bioaerosol samples by high (≥ 1000 ppm) or low (< 1000 ppm) CO 2 concentration in classrooms. Results: We collected 173 nasal swabs from 100 participants and 30 bioaerosol samples from 10 rooms. Participants were mostly female (68%) and white (60%). Viruses were detected in 90% of bioaerosol and 35% of nasal samples. Four classrooms and both common spaces had the same virus detected in bioaerosol and nasal swab samples. None of the spaces met the CDC recommended ACH of 5, and only one exceeded ANSI/ASHRAE 62.1‐2022 standards for outdoor air supply. During school hours, 83% of classrooms had high average CO 2 concentrations. Classrooms with high CO 2 levels had higher viral detection. Conclusions: Viral presence was found in bioaerosol and nasal samples with some overlap in concurrently collected samples. Findings suggest a possible connection between high CO 2 levels and virus detection. Improving IAQ and ventilation may reduce respiratory infection risks in schools. However, this study highlights the need to further assess the impact of various environmental modifications on respiratory virus transmission in schools, including determining optimal strategies such as ventilation, filtration, or germicidal ultraviolet energy.

8 April 2026 in Journal of Clinical Microbiology
Verified
Journal Article
Open access
MNMarisa Nielsen
Marisa Nielsen
PRPing Ren
Ping Ren
SKSri Bharathi Kavuri
Sri Bharathi Kavuri
KCKarissa Culbreath
Karissa Culbreath
RSRangaraj Selvarangan
Rangaraj Selvarangan
JFJanet Farhang
Janet Farhang
Respiratory tract infections remain a major cause of global morbidity, highlighting the need for rapid and accurate diagnostic testing. This multicenter study evaluated the clinical and analytical performance of the updated NxTAG Respiratory Pathogen Panel v2 (RPPv2), a high-throughput multiplex molecular assay designed to detect 21 viral and bacterial respiratory pathogens. A total of 2,145 nasopharyngeal swab specimens, including both prospectively enrolled and archived specimens, were analyzed across five U.S. clinical sites. The NxTAG RPPv2 was assessed against FDA-cleared molecular assays and bi-directional sequencing, with contrived specimens used to supplement low-prevalence targets. Valid results were obtained for 99.7% of specimens after a single retest, with minimal performance differences between fresh and frozen specimens. Among viral targets, 15 of 18 (one viral target did not have clinical positive specimens for analysis) achieved ≥95% positive percent agreement (PPA) across the prospective and pre-selected arms. For bacterial targets, Mycoplasma pneumoniae and Chlamydia pneumoniae showed PPA values of 92.3% and 100%, respectively. Lower PPA values were observed for parainfluenza 4 (90.3%). Negative percent agreement (NPA) was consistently high across targets, with all viral and bacterial analytes achieving ≥99.2%. Reproducibility across sites and operators was 99.9%. Overall, the NxTAG RPPv2 demonstrated high accuracy, reproducibility, and operational efficiency, supporting its clinical utility for rapid and reliable diagnosis of respiratory tract infections. IMPORTANCE: Respiratory infections remain a major global health challenge, particularly during seasonal epidemics and pandemics. Rapid and accurate pathogen detection is essential to guide treatment decisions, limit transmission, and reduce unnecessary antibiotic use. This multicenter study evaluated the updated NxTAG Respiratory Pathogen Panel v2 (RPPv2), a high-throughput molecular assay capable of detecting 22 common viral and bacterial respiratory pathogens from a single sample. The panel demonstrated high accuracy, reproducibility, and reliability across multiple clinical sites and sample types, including both fresh and frozen specimens. These findings support the NxTAG RPPv2 as a comprehensive, efficient diagnostic tool that can support respiratory infection diagnosis and contribute to multifaceted antimicrobial stewardship efforts.

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
LGLuke C Gard
Luke C Gard
JGJennifer Goldman
Jennifer Goldman
RSRangaraj Selvarangan
Rangaraj Selvarangan
ASAnjana Sasidharan
Anjana Sasidharan
DBDithi Banerjee
Dithi Banerjee
JSJennifer Schuster
Jennifer Schuster
The COVID-19 pandemic highlighted the need for better data to understand how ventilation may impact respiratory virus transmission. We evaluated if there was an association between respiratory viruses detected in school room air samples and nasal swabs from students/ staff in the same room. We performed air and respiratory sampling to detect respiratory viruses at 3 time points between Feb 27 - Mar 28, 2023 in 2 elementary schools. Three classrooms, a multipurpose room, and school nurse’s office in each school had 1 air sample/ room collected using Thermo Scientific AerosolSense™ sampler during 8 school hours. Concomitant respiratory viral testing, using self-collected nasal swabs, was performed in students/ staff enrolled in a respiratory virus surveillance school testing program. Air and respiratory specimens were tested for adenovirus (AdV); coronaviruses (CoV) 229E, HKU1, NL63, OC43; human metapneumovirus (hMPV), influenza A and B (Flu), parainfluenza virus 1-4 (PIV), respiratory syncytial virus (RSV), rhinovirus/ enterovirus (RV/EV), and SARS-CoV-2 using the Hologic® Panther Fusion® Respiratory Assay. Detected respiratory viruses in room air and respiratory samples were compared to determine likelihood of capturing current human respiratory viral infections in room air and additional viruses circulating from unsampled students/ staff in the same room. RV and AdV in human respiratory samples were typed by partial genomic sequencing to understand if viruses were similar. Concomitant respiratory virus detection from student and staff nasal swabs and air samplers (N=student/staff tested per room) Concomitant respiratory virus surveillance in air samples and students/ staff can be performed to better understand the role of ventilation and respiratory virus transmission. Additional studies, including sequencing data and symptom assessment, are needed. Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support

27 November 2023 in Open Forum Infectious Diseases
Verified
Journal Article
Open access
PDF file
ASAnjana Sasidharan
Anjana Sasidharan
DBDithi Banerjee
Dithi Banerjee
AHAmanda M Hayes
Amanda M Hayes
SPSydnie Petty
Sydnie Petty
JSJennifer Schuster
Jennifer Schuster
RSRangaraj Selvarangan
Rangaraj Selvarangan
Between January 2023 and March 2023, self-collected nasal swabs in UTM from children and staff with ARI symptoms were collected as part of an ongoing school-based surveillance study in a large Missouri school district. Samples were tested on the QIAstat-Dx Respiratory SARS-CoV-2 Panel and the fully automated Hologic Panther Fusion system, which can detect a total of 21 respiratory viruses. Percent Agreement analysis was performed to compare the performance of each platform. Of 200 samples collected, QIAstat detected viruses in 111 samples (55.5%) and Hologic in 115 samples (57.5%). Both assays showed high overall agreement (90%), with a PPA (Positive percentage agreement) of 89%, an NPA (Negative percentage agreement) of 94%. Parainfluenza (PIV) showed 100% PPA and NPA followed by adenovirus (Adv) (PPA: 100%; NPA: 97.9%) and rhinovirus (RV) (PPA: 92% and NPA: 94%). Human metapneumovirus (hMPV) had the lowest PPA (47%) but a high NPA (99%) (Table 1). The median CT values for QIAstat and Hologic were 28.8 (IQR 23.65 - 32.5) and 29.3 (IQR 24.2 – 34.5), respectively. QIAstat missed 19 detections, including hMPV (9, 53%), coronavirus NL63 (4, 16%), and RV (4, 8%), with a corresponding median Ct of 39.1 (IQR 34.5 – 41.2) on Hologic. Hologic missed 12 detections, with RV being the most common target (9, 17%), and a corresponding median Ct of 32.9 (IQR: 30.3-35.5) on QIAstat. QIAstat and Hologic exhibit comparable performance (overall agreement 90%) for detecting viral respiratory pathogens from self-collected nasal swabs. Viral detections missed by QIAstat assay had low viral loads, while targets missed by Hologic assay had moderate viral load; additional investigation is needed. Our findings suggest that both STA platforms are suitable for diagnosing respiratory viral infections in self-collected nasal swabs in school-setting. Rangaraj Selvarangan, BVSc, PhD, D(ABMM), FIDSA, FAAM, Abbott: Honoraria|Altona Diagnostics: Grant/Research Support|Baebies Inc: Advisor/Consultant|BioMerieux: Advisor/Consultant|BioMerieux: Grant/Research Support|Bio-Rad: Grant/Research Support|Cepheid: Grant/Research Support|GSK: Advisor/Consultant|Hologic: Grant/Research Support|Lab Simply: Advisor/Consultant|Luminex: Grant/Research Support